[go: up one dir, main page]

MX373138B - Inhalador de polvo seco y método de uso. - Google Patents

Inhalador de polvo seco y método de uso.

Info

Publication number
MX373138B
MX373138B MX2015007912A MX2015007912A MX373138B MX 373138 B MX373138 B MX 373138B MX 2015007912 A MX2015007912 A MX 2015007912A MX 2015007912 A MX2015007912 A MX 2015007912A MX 373138 B MX373138 B MX 373138B
Authority
MX
Mexico
Prior art keywords
dry powder
dose
powder inhaler
patient
mouthpiece
Prior art date
Application number
MX2015007912A
Other languages
English (en)
Other versions
MX2015007912A (es
Inventor
Kambiz Yadidi
Original Assignee
Otitopic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50973229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX373138(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otitopic Inc filed Critical Otitopic Inc
Publication of MX2015007912A publication Critical patent/MX2015007912A/es
Publication of MX373138B publication Critical patent/MX373138B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)

Abstract

Son proporcionados métodos que reducen el riesgo de un evento tromboembálico, y un sistema relacionado de suministro de fármaco. En algunas modalidades, una dosis de ácido acetilsalicílico puede ser proporcionada en forma de polvo a un paciente utilizando un inhalador de polvo seco. La dosis puede ser efectiva para reducir el riesgo de un evento tromboembálico en un paciente. Un inhalador de polvo seco utilizado por el método puede tener una boquilla, un recipiente que recibe la dosis de ácido acetilsalicílico, y un miembro de accionamiento que hace disponible la dosis de ácido acetilsalicílico para su inhalación por un paciente a través de la boquilla.
MX2015007912A 2012-12-20 2013-03-15 Inhalador de polvo seco y método de uso. MX373138B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261740407P 2012-12-20 2012-12-20
US13/791,734 US9757395B2 (en) 2012-12-20 2013-03-08 Dry powder inhaler and methods of use
PCT/US2013/032597 WO2014098945A1 (en) 2012-12-20 2013-03-15 Dry powder inhaler and methods of use

Publications (2)

Publication Number Publication Date
MX2015007912A MX2015007912A (es) 2016-03-03
MX373138B true MX373138B (es) 2025-03-04

Family

ID=50973229

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2015007912A MX373138B (es) 2012-12-20 2013-03-15 Inhalador de polvo seco y método de uso.
MX2020003436A MX2020003436A (es) 2012-12-20 2013-03-15 Inhalador de polvo seco y metodo de uso.
MX2022009231A MX2022009231A (es) 2012-12-20 2015-06-18 Inhalador de polvo seco y metodo de uso.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2020003436A MX2020003436A (es) 2012-12-20 2013-03-15 Inhalador de polvo seco y metodo de uso.
MX2022009231A MX2022009231A (es) 2012-12-20 2015-06-18 Inhalador de polvo seco y metodo de uso.

Country Status (14)

Country Link
US (1) US9757395B2 (es)
EP (3) EP2934134B1 (es)
JP (1) JP6416779B2 (es)
CN (1) CN105007731A (es)
AU (1) AU2016213728B2 (es)
CA (2) CA3033296A1 (es)
DK (2) DK3613421T3 (es)
ES (2) ES2946261T3 (es)
FI (1) FI3613421T3 (es)
HU (1) HUE062264T2 (es)
MX (3) MX373138B (es)
PL (2) PL3613421T3 (es)
PT (2) PT3613421T (es)
WO (1) WO2014098945A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
EP3607941A1 (en) 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
JP6701086B2 (ja) 2014-02-20 2020-05-27 オティトピック インコーポレイテッド 吸入用の乾燥粉末製剤
AU2015296142A1 (en) * 2014-07-31 2017-02-23 Otitopic Inc. Dry powder formulations for inhalation
US10568894B2 (en) 2016-06-03 2020-02-25 Otitopic Inc. Dry powder formulations for inhalation
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
AU2017432640B2 (en) 2017-09-22 2023-11-30 Vectura Inc. Dry powder compositions with magnesium stearate
US11759397B2 (en) 2020-10-07 2023-09-19 S&SX-ray Products, Inc. Medication dispensing arrangement without scanning

Family Cites Families (198)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2224175B1 (es) 1973-04-04 1978-04-14 Isf Spa
BR8007911A (pt) 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
US4885287A (en) * 1988-08-09 1989-12-05 University Of Kentucky Research Foundation Novel method of administering aspirin and dosage forms containing same
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
EP0499142A3 (en) 1991-02-09 1993-05-05 Hoechst Aktiengesellschaft Potentiation of the antireactive-antiasthmatic effect of inhaled loop diuretics by inhaled non steroidal anti-flammatory drugs
DE69229070T2 (de) 1991-02-09 1999-11-18 B.S.D. Bio Science Development Snc Di Omini C. & Zuccari G., Bussero Antireaktive antiasthmatische Wirkung von Acetylsalicylsäure durch Inhalation
US5256538A (en) 1991-03-08 1993-10-26 Board Of Regents, The University Of Texas System Detection of early platelet activation and prediagnosis of thrombotic events
US5327883A (en) 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
US5639441A (en) 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
US6098620A (en) * 1993-01-29 2000-08-08 Aradigm Corporation Device for aerosolizing narcotics
US20070117863A1 (en) 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
PT101450B (pt) 1994-02-02 1999-11-30 Hovione Produtos Farmaceuticos Novo dispositivo para inalacao
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6136346A (en) 1995-04-14 2000-10-24 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
US6209538B1 (en) 1995-08-02 2001-04-03 Robert A. Casper Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament
US5875776A (en) 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6284282B1 (en) 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
IL143046A0 (en) 1998-11-12 2002-04-21 Pilkiewicz Frank G An inhalation system
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
JP3739955B2 (ja) 1999-01-11 2006-01-25 株式会社日立製作所 吸入式投薬器
US6630169B1 (en) 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
US7919119B2 (en) 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
WO2001026720A1 (en) 1999-10-12 2001-04-19 Shl Medical Ab Inhaler
US20030176421A1 (en) 1999-12-30 2003-09-18 Watson John W. Prokinetic agents for treating gastric hypomotility and related disorders
EP1261316B1 (en) 2000-02-28 2008-04-23 PharmaKodex Limited Device for the delivery of oral drugs
US6998137B2 (en) 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0010709D0 (en) 2000-05-03 2000-06-28 Vectura Ltd Powders for use a in dry powder inhaler
AU765944B2 (en) 2000-06-12 2003-10-02 Teijin Limited Powder medicine multiple dose administration device
EP1177805A1 (en) 2000-07-31 2002-02-06 Maryland Financial Inc. Powder inhaler
FR2812545B1 (fr) 2000-08-03 2003-03-28 Air Liquide Sante Int Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur
WO2002011695A2 (en) 2000-08-07 2002-02-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
US20020025917A1 (en) 2000-08-28 2002-02-28 Edward Pappalardo Compartmentalized device to enable a process of liquefying and administering aspirin as a first aid to heart attack victims
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
BR0115524A (pt) 2000-12-22 2003-09-16 Aspen Aerogels Inc Pó seco dispersìvel para transferência pulmonar e método de tratamento de um estado de doença responsivo ao tratamento por meio de um agente terapêutico
CA2432644C (en) 2000-12-25 2013-07-23 Fumitoshi Asai Pharmaceutical composition comprising aspirintm and cs-747
JP4874482B2 (ja) 2000-12-25 2012-02-15 第一三共株式会社 アスピリンを含有する医薬組成物
EP1238680B1 (en) 2001-03-05 2003-12-10 Ivo Pera Inhaling device for dispersing powdered medicaments contained in a capsule through the respiratory tract
US20060293217A1 (en) 2001-03-19 2006-12-28 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
US6455028B1 (en) 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
US20040049022A1 (en) 2001-04-24 2004-03-11 Nyce Jonathan W. Composition & methods for treatment and screening
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
GB0129270D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Pharmaceutical combination
GB0129397D0 (en) 2001-12-07 2002-01-30 Pfizer Ltd Pharmaceutical combination
ITMI20020078A1 (it) 2002-01-16 2003-07-16 Fabrizio Niccolai Dispositivo utilizzabile nel tratamento di affezzioni delle vie respiratorie
WO2003072080A1 (en) 2002-02-22 2003-09-04 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
SE524990C2 (sv) 2002-04-12 2004-11-09 Microdrug Ag Preparation av terapeutiskt torrt pulver samt förfarande för uppdelning och spridning i luft av medicinskt pulver
US7405207B2 (en) 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
AU2003276131A1 (en) 2002-06-18 2003-12-31 Epigenesis Pharmaceuticals, Inc. A dry powder oligonucleotide formulation, preparation and its uses
CN1694689A (zh) 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
GB0226105D0 (en) 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
US7516741B2 (en) 2002-12-06 2009-04-14 Novartis Ag Aerosolization apparatus with feedback mechanism
US7284553B2 (en) 2002-12-12 2007-10-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder inhaler comprising a chamber for a capsule for taking up a non-returnable capsule being filled with an active ingredient
SE0203687D0 (sv) 2002-12-13 2002-12-13 Ian Harwigsson Med Adagit Fa Pharmaceutical Porous Particles
US20040206350A1 (en) 2002-12-19 2004-10-21 Nektar Therapeutics Aerosolization apparatus with non-circular aerosolization chamber
US7669596B2 (en) 2002-12-31 2010-03-02 Novartis Pharma Ag Aerosolization apparatus with rotating capsule
US7878193B2 (en) 2003-01-14 2011-02-01 Boehringer Ingelheim International Gmbh Capsule for taking an active substance which can be inhaled
EP1610850B2 (en) 2003-04-09 2020-08-05 Novartis AG Aerosolization apparatus with air inlet shield
DK1615689T3 (da) 2003-04-09 2016-03-14 Novartis Ag Apparatur til dannelse af en aerosol og omfattende en opretningsføring til punktering af en kapsel
EP1622625A1 (en) 2003-04-09 2006-02-08 Wyeth Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo [5.2.o] non-1 (7)-en-2-yl )alkyl] phosphonic acid and derivatives and methods of use thereof
GB0312419D0 (en) 2003-05-30 2003-07-02 Boots Healthcare Int Ltd Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess
AU2004249166B2 (en) 2003-06-13 2008-10-09 Alkermes, Inc. Low dose pharmaceutical powders for inhalation
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
US20050142201A1 (en) 2003-07-18 2005-06-30 Julia Rashba-Step Methods for fabrication, uses and compositions of small spherical particles of hGH prepared by controlled phase separation
JP2007502815A (ja) 2003-08-20 2007-02-15 イーライ リリー アンド カンパニー Ｐｐａｒ調節因子
EP1658060A2 (en) 2003-08-22 2006-05-24 Boehringer Ingelheim Pharmaceuticals Inc. Methods of treating copd and pulmonary hypertension
US20050249697A1 (en) 2003-09-24 2005-11-10 Uhrich Kathryn E Compositions and methods for the inhibition of bone growth and resorption
GB2407040B (en) 2003-10-15 2007-09-19 Sheikh Arshad Saeed Anti-platelet aggregation compositions
WO2005040163A1 (en) 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
WO2005041886A2 (en) 2003-10-31 2005-05-12 Metaphore Pharmaceuticals, Inc. Methods for generating or increasing revenues related to pain inhibitor commerce
US20070232575A1 (en) 2004-02-05 2007-10-04 Baulieu Etienne E Treatment of Pulmonary Artery Hypertension with Dhea, Dheas, Dhea Analogs, or Dhea Derivatives
EP1722767A2 (en) 2004-02-23 2006-11-22 Prolexys Pharmaceuticals, Inc. NON-PEPTIDYL AGENTS WITH pHSP20-LIKE ACTIVITY, AND USES THEREOF
KR20120089705A (ko) 2004-04-23 2012-08-13 사이덱스 파마슈티칼스, 인크. 술포알킬 에테르 시클로덱스트린 함유 ｄｐｉ 제형
EP1756042B8 (en) 2004-05-04 2014-06-04 RaQualia Pharma Inc Substituted methyl aryl or heteroaryl amide compounds
US7189750B2 (en) 2004-05-05 2007-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof
US7968575B2 (en) 2004-05-05 2011-06-28 Renopharm Ltd. Nitric oxide donors and uses thereof
CN101151048A (zh) 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
US7556035B2 (en) 2004-05-28 2009-07-07 Quadrant Technologies Limited Unit dose dry powder inhaler
WO2006017354A1 (en) 2004-07-13 2006-02-16 Pharmacofore, Inc. Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing disease or pain
US20060030550A1 (en) 2004-08-04 2006-02-09 Lithgow Theodore L Pharmaceutical formulations
WO2006060117A2 (en) 2004-11-02 2006-06-08 The Board Of Trustees Of The Leland Stanford Junior University Methods for inhibition of nkt cells
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
ITMI20050417A1 (it) 2005-03-15 2006-09-16 Medestea Res & Production S R L Uso di farmaci anti-infiammatori non steroidei per via inalatoria nella terapia della bronchite acuta e cronica
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2007014391A2 (en) 2005-07-27 2007-02-01 Nastech Pharmaceutical Company Inc. Tight junction modulating peptide components for enhancing mucosal delivery of therapeutic agents
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
EP1973523A2 (en) 2005-12-15 2008-10-01 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
US7651770B2 (en) 2005-12-16 2010-01-26 The University Of Kansas Nanoclusters for delivery of therapeutics
WO2007072503A2 (en) 2005-12-21 2007-06-28 Panacea Biotec Ltd. Combinations for managing inflammation and associated disorders
US7201929B1 (en) * 2005-12-30 2007-04-10 Alan James Group, Llc. Aspirin formulation for cardiovascular health
KR102109867B1 (ko) 2006-01-24 2020-05-13 안선 바이오파르마, 아이엔씨. 고분자 미소 구체들의 조제를 위한 기술
GB0602049D0 (en) * 2006-02-01 2006-03-15 Trumeter Company Ltd Inhaler
GB0605723D0 (en) 2006-03-23 2006-05-03 3M Innovative Properties Co Powder filling processes
PT103481B (pt) * 2006-05-16 2008-08-01 Hovione Farmaciencia S A Inalador de uso simples e método de inalação
US7806117B2 (en) 2006-06-07 2010-10-05 Shin Nippon Biomedical Laboratories, Ltd. Peroral powder delivery device
US8201555B2 (en) 2006-06-27 2012-06-19 Brintech International Limited Inhaler
PL2068889T3 (pl) 2006-08-10 2020-06-29 Roy C. Levitt Anakinra do zastosowania do leczenia zespołu zarostowego zapalenia oskrzelików
GB0617171D0 (en) 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
GB0621957D0 (en) 2006-11-03 2006-12-13 Vectura Group Plc Inhaler devices and bespoke pharmaceutical compositions
NL1033047C2 (nl) 2006-12-13 2008-06-16 Pharmachemie Bv Capsule, gevuld met een medicijn, in het bijzonder een inhaleerbaar medicijn.
GB0625303D0 (en) 2006-12-19 2007-01-24 Jagotec Ag Improvements in and relating to metered dose inhalers
GB0700839D0 (en) 2007-01-17 2007-02-21 Braithwaite Philip Device
EP1964564A1 (en) 2007-04-19 2008-09-03 LAB International SRL Breakthrough Pain Management
US8530463B2 (en) 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
CA2687720A1 (en) 2007-06-13 2008-12-24 Amgen Inc. Il-17 heteromeric receptor complex
JP2010533181A (ja) 2007-07-13 2010-10-21 アボツト・バイオテクノロジー・リミテツド ＴＮＦα阻害剤の肺投与のための方法及び組成物
US20090098207A1 (en) 2007-07-24 2009-04-16 Nexbio, Inc. Technology for the Preparation of Microparticles
US9358242B2 (en) 2007-08-30 2016-06-07 Prelief Inc. Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
CA2707906A1 (en) 2007-12-05 2009-06-18 Novartis Ag Receptacle for an aerosolizable pharmaceutical formulation
EP2227085A4 (en) 2007-12-06 2013-10-09 Berg Pharma Llc INGREDIBLE COMPOSITIONS WITH INCREASED BIOLOGICAL AVAILABILITY
AU2008345034A1 (en) 2007-12-27 2009-07-09 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide - donating compounds and uses thereof
DE102008004386A1 (de) 2008-01-14 2009-07-23 Activaero Gmbh Verwendung eines Acetylsalicylsäuresalzes zur Behandlung viraler Infektionen
JP2011510017A (ja) 2008-01-15 2011-03-31 ユニベルシテ・ドウ・ストラスブール 治療薬として有用なレゾルシン酸ラクトンの合成
KR101240904B1 (ko) 2008-02-21 2013-03-11 키린-암젠 인코포레이티드 Ｉｌ-１７ｒａ-ｉｌ-１７ｒｂ 길항제 및 그의 용도
GB0803369D0 (en) 2008-02-25 2008-04-02 Helperby Therapeutics Ltd Biological materials and uses thereof
AU2009231953A1 (en) 2008-04-04 2009-10-08 Irm Llc Compounds and compositions as ITPKB inhibitors
JP2011518155A (ja) 2008-04-15 2011-06-23 サーコード コーポレイション 免疫関連障害の局所治療に使用するためのエアゾール化ｌｆａ−１アンタゴニスト
EP2300469B1 (en) 2008-05-13 2015-06-24 Novartis AG Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
US20110112134A1 (en) 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
KR101762089B1 (ko) 2008-06-13 2017-07-26 맨카인드 코포레이션 건조 분말 흡입기 및 약물 투여 시스템
US20110189106A1 (en) 2008-07-15 2011-08-04 Schering Corporation Intranasal compositions, dosage forms and methods of treatment
MX2011000405A (es) 2008-07-18 2011-03-04 Prosonix Ltd Proceso para mejorar la cristalinidad.
WO2010011329A2 (en) 2008-07-23 2010-01-28 Map Pharmaceuticals, Inc. The delivery of powdered drug via inhalation
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
RU2519193C2 (ru) 2008-09-12 2014-06-10 Критикал Фармасьютикалс Лимитед Усовершенствование всасывания терапевтических средств через слизистые оболочки или кожу
CA2755543A1 (en) 2009-03-13 2010-09-16 Nucitec S.A. De C.V. Compositions and methods for treatment and prevention of cardiovascular disease
ES2625260T5 (es) 2009-03-26 2020-07-29 Pulmatrix Operating Co Inc Formulaciones de polvo seco y métodos para el tratamiento de enfermedades pulmonares
WO2010117951A1 (en) 2009-04-06 2010-10-14 The Regents Of The University Of California Inhibitors of soluble epoxide hydrolase to inhibit or prevent niacin-induced flushing
CN102459270B (zh) 2009-04-20 2015-04-29 奥斯拜客斯制药有限公司 Janus激酶3的哌啶抑制剂
GB0908129D0 (en) 2009-05-12 2009-06-24 Innovata Ltd Composition
US9101539B2 (en) 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
EP3332826A1 (en) 2009-05-18 2018-06-13 Adamis Pharmaceuticals Corporation Dry powder inhaler with a dose counter
CN102458543B (zh) 2009-05-18 2015-02-04 3M创新有限公司 干粉吸入器
US20120125325A1 (en) 2009-06-01 2012-05-24 Robin Mark Bannister The use of amlexanox in the therapy of neutrophil-driven diseases
GB201111485D0 (en) 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
GB0917054D0 (en) 2009-09-29 2009-11-11 Cytoguide As Agents, uses and methods
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
GB0918431D0 (en) 2009-10-21 2009-12-09 Prosonix Ltd Process for improving crystallinity
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
BR112012025568A2 (pt) 2010-04-07 2017-03-28 Abbvie Inc proteínas de ligação ao tnf-<244>.
CN105640925B (zh) 2010-08-30 2019-08-16 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
US8883844B2 (en) 2010-09-24 2014-11-11 Nitrogenix Inc. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
WO2012061902A1 (en) 2010-11-12 2012-05-18 Monash University Micronised spray-dried particles comprising polymyxin
US8561609B2 (en) * 2010-12-07 2013-10-22 Respira Therapeutics, Inc. Dry powder inhaler
CN102058886A (zh) 2010-12-20 2011-05-18 云南白药集团无锡药业有限公司 医用粉雾剂及其应用
WO2012107364A1 (en) 2011-02-07 2012-08-16 Scipharm Sàrl Novel composition for the treatment of cystic fibrosis
GB201102237D0 (en) 2011-02-09 2011-03-23 Kuecept Ltd Particle formulation
CN108014340A (zh) 2011-04-12 2018-05-11 莫伊莱麦屈克斯公司 用于预防或治疗以成纤维细胞异常增殖及细胞外基质沉积为特征的疾病的组合物和方法
WO2012174557A1 (en) 2011-06-17 2012-12-20 Berg Pharma Llc Inhalable pharmaceutical compositions
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
EA201490538A1 (ru) 2011-09-06 2014-08-29 Верона Фарма Плк Лечение кашля и его приступов
DK2790758T3 (da) 2011-12-16 2017-11-20 Indosys Ltd Kassette til en lægemiddeldosis og tilførselsindretning
EP2809686A4 (en) 2012-01-31 2015-11-25 Cerulean Pharma Inc POLYMERS ON CYCLODEXTRINBASIS FOR THERAPEUTIC ADMINISTRATION
CN104703584B (zh) 2012-02-28 2019-05-31 艾塞尤提卡控股公司 可吸入药物组合物
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
ES2625727T3 (es) 2012-03-26 2017-07-20 Arroyo Biosciences L.L.C. Nuevos antagonistas de receptores de esfingosina-1-fosfato
GB201205632D0 (en) 2012-03-30 2012-05-16 Vectura Ltd Method and apparatus
NZ741873A (en) 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
SG11201407676VA (en) 2012-05-21 2015-03-30 Agency Science Tech & Res A dry powder formulation
ES2658972T3 (es) 2012-06-20 2018-03-13 University Of Waterloo Sistema de administración de nanopartículas mucoadhesivas
US9586931B2 (en) 2012-09-28 2017-03-07 Merck Sharp & Dohme Corp. Triazolyl derivatives as Syk inhibitors
EP2903622A1 (en) 2012-10-03 2015-08-12 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza with invariant nkt cell agonists
US20150284381A1 (en) 2012-11-07 2015-10-08 Merck Sharp & Dohme Corp. Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
KR20200105983A (ko) 2013-01-28 2020-09-09 인코젠 쎄라퓨틱스 프라이빗 리미티드 로플루밀라스트 n- 옥사이드의 흡입에 의한 자가면역, 호흡 및 염증성 장애의 치료방법
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
GB201305813D0 (en) 2013-03-28 2013-05-15 Vectura Ltd Compositions and methods
EP3607941A1 (en) 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
JP2016534976A (ja) 2013-05-23 2016-11-10 アズセラピーズ インコーポレイテッド クロモリンを送達する方法
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
CA2926793C (en) 2013-10-11 2022-11-22 Lawrence S. ZISMAN Spray-dry formulations for treating pulmonary arterial hypertension
JP6701086B2 (ja) 2014-02-20 2020-05-27 オティトピック インコーポレイテッド 吸入用の乾燥粉末製剤
JP6619745B2 (ja) 2014-02-20 2019-12-11 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 補体成分ｃ５抗体
SG11201606983SA (en) 2014-02-27 2016-09-29 Allergan Inc COMPLEMENT FACTOR Bb ANTIBODIES
CN106715443A (zh) 2014-03-26 2017-05-24 坎格特生物技术制药有限责任公司 Fl118母核化学结构平台产生用于治疗人类疾病的fl118衍生物的用途
EP3126004A4 (en) 2014-04-02 2017-11-29 Rogne Bioscience Inc. Methods and compositions for treating inflammatory disorders
WO2015155544A1 (en) 2014-04-10 2015-10-15 Patrick Crowley Delivery of non-steroidal antiinflammatory agents to the brain via the nasal tract to treat neurological disorders

Also Published As

Publication number Publication date
CA2895398A1 (en) 2014-06-26
MX2022009231A (es) 2022-09-07
CA2895398C (en) 2019-02-12
HUE062264T2 (hu) 2023-10-28
JP2016504109A (ja) 2016-02-12
EP3613421B1 (en) 2023-05-03
MX2015007912A (es) 2016-03-03
EP4233874A3 (en) 2023-11-01
AU2016213728A1 (en) 2016-08-25
AU2013205497A1 (en) 2014-07-10
EP4233874A2 (en) 2023-08-30
CA3033296A1 (en) 2014-06-26
PT2934134T (pt) 2019-12-03
ES2946261T3 (es) 2023-07-14
JP6416779B2 (ja) 2018-10-31
AU2016213728B2 (en) 2018-11-01
PL3613421T3 (pl) 2023-07-31
US20140174437A1 (en) 2014-06-26
EP2934134B1 (en) 2019-09-25
PL2934134T3 (pl) 2020-04-30
MX2020003436A (es) 2022-07-27
DK3613421T3 (da) 2023-06-12
EP3613421A1 (en) 2020-02-26
ES2759319T3 (es) 2020-05-08
US9757395B2 (en) 2017-09-12
WO2014098945A1 (en) 2014-06-26
CN105007731A (zh) 2015-10-28
PT3613421T (pt) 2023-06-19
DK2934134T3 (da) 2019-11-25
FI3613421T3 (fi) 2023-06-07
EP2934134A1 (en) 2015-10-28
EP2934134A4 (en) 2016-08-17

Similar Documents

Publication Publication Date Title
MX373138B (es) Inhalador de polvo seco y método de uso.
CY1121373T1 (el) Μεθοδος και φαρμακοτεχνικη μορφη για εισπνοη
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
CY1123937T1 (el) Σκευασμα ξηρης σκονης που περιλαμβανει ενα αντιχολινεργικο, ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο για χορηγηση δια εισπνοης
PH12015502593A1 (en) COMPOSITIONS, METHODS and SYSTEMS FOR RESPIRATORY DELIVERY OF THREE OR MORE ACTIVE AGENTS
EA201400591A1 (ru) Ингалятор
TN2014000322A1 (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
MY170349A (en) Nasal delivery devices
EP3016708A4 (en) Metered dose inhaler and methods thereof
MX2015011610A (es) Nebulizador para bebes y pacientes con compromiso respiratorio.
TR201008226A2 (tr) Kapsül içeren bir inhalasyon cihazı.
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
EA201301264A1 (ru) Способ получения неорганического материала в виде частиц
WO2014007772A3 (en) Inhalation compositions comprising glucose anhydrous
ZA201506675B (en) New stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
WO2014007771A3 (en) Inhalation compositions comprising muscarinic receptor antagonist
PH12015500374A1 (en) Extended release compositions of an aminoalkyl nitrate
GB2507433A (en) A housing for an oral hygiene and medication device, and an assembly thereof
BR112013005283A2 (pt) atuador de inalador dosimetrado, de inalador dosimetrado e uso de um atuador
WO2014177703A3 (de) Inhalator für ein dosieraerosol
UA116011C2 (uk) Частинки фенілефрину резинату та їх використання у фармацевтичних композиціях
MY162322A (en) Polysaccharide polymer from the seeds of the tamarind tree for use in treating dry cough
PT2617451T (pt) Conjunto para administrar um medicamento e inalador de dose única para a administração de um medicamento em pó que tenha esse conjunto
WO2013109213A3 (en) Pharmaceutical formulations comprising tiotropium

Legal Events

Date Code Title Description
FG Grant or registration